Altimmune
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Altimmune sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
Altimmune: 16 sponsored US clinical trials, 1 recruiting.
Altimmune sponsors 16 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 12 completed. 1 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Influenza, with 2 trials.
Top-decile sponsor footprint
Altimmune ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
12 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
16 total, page 1 of 1
RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
NCT07009860
RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
NCT06987513
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
NCT05989711
Efficacy and Safety of ALT-801 in the Treatment of Obesity
NCT05295875
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
NCT05292911
ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
NCT05134662
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
NCT05006885
Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)
NCT04679909
HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)
NCT04684914
NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
NCT04442230
NasoShield in Healthy Adults to Study Safety and Immunogenicity
NCT04415749
Study of the Safety and Immunogenicity of NasoVAX Extension
NCT03760549
NasoShield Study of Safety and Immunogenicity
NCT03352466
Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
NCT03232567
Immune Response Following Seasonal Influenza Vaccination
NCT03163342
Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.
NCT00755703
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 7 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Altimmune pipeline
1 recruiting of 16 indexed (6% open); 12 completed (75%).
Phase mix: 1 late (III/IV) vs 14 early (I/II) (early-phase heavy).
Top condition: Influenza (2 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Altimmune: open-pipeline peers nationwide
Peers matched on 16 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Altimmune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 trials (± recruiting share)
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
- A.T. Still University of Health Sciences · 16 trials · 0% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Albert Einstein Healthcare Network · 6% recruiting · 48 trials
- Bassett Healthcare · 6% recruiting · 16 trials
- Dynavax Technologies Corporation · 6% recruiting · 16 trials
- East Tennessee State University · 6% recruiting · 16 trials
Related
What to do with this Altimmune page
16 registered trials is a research-attention snapshot, not an endorsement of Altimmune or any single study.
- 1 of Altimmune's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Influenza is the condition Altimmune studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Influenza trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Altimmune pipeline card: 16 registered trials from official public datasets.Report a data error.